Physician profile
Arvind Madaan
NPI 1699854307
$7,627.83
in general payments reported to CMS, 2019-2025
26 companies · $1,976 in 2025
The $1,976 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $1,493 · 2021: $375 · 2022: $604 · 2023: $1,126 · 2024: $1,265 · 2025: $1,976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,332 · Consulting Fee: $28.87 · Education: $6.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,331.84 |
| Consulting Fee | $28.87 |
| Education | $6.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $1,284.87 | 2020-2023 | Ayvakit |
| Regeneron Healthcare Solutions, INC. | $944.16 | 2020-2025 | Dupixent |
| Grifols USA, LLC | $689.95 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Glaxosmithkline, LLC. | $646.61 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $605.61 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genentech USA, INC. | $601.72 | 2019-2025 | Xolair |
| Kaleo, INC. | $473.67 | 2019-2024 | Auvi-Q |
| Amgen INC. | $415.82 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $383.36 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $347.93 | 2025 | Neffy |
| Genzyme Corporation | $346.42 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.01 | 2021-2025 | Takhzyro, Hyqvia, Cuvitru |
| Biocryst US Sales Co., LLC | $131.82 | 2021-2025 | Orladeyo |
| Ionis Pharmaceuticals, INC. | $61.21 | 2025 | Dawnzera, Donidalorsen |
| Csl Behring | $59.18 | 2021-2025 | Hizentra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $57.80 | 2019-2023 | Alternaria Tenuis, Pre-Pen, Standardized Mite D. Farinae |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.66 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $45.08 | 2019-2021 | |
| Pharming Healthcare, INC. | $43.18 | 2023 | Ruconest |
| Pfizer INC. | $35.04 | 2021-2025 | |
| Adma Biomanufacturing LLC | $28.87 | 2025 | |
| Hospira, INC. | $24.22 | 2023 | |
| Aimmune Therapeutics, INC. | $23.22 | 2022 | |
| Incyte Corporation | $18.24 | 2022 | |
| Optinose US, INC. | $16.98 | 2019 | |
| Shire North American Group INC | $13.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Madaan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.